PSMA 抑制剂 18F-DCFPyL-PET-CT 图像对前列腺癌的诊断准确率如何？
How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer?
机构信息
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.
Department of Radiology, Molecular Imaging, Seattle Cancer Care Alliance, and Nuclear Medicine, University of Washington, Seattle, Washington.
出版信息
Clin Cancer Res. 2021 Jul 1;27(13):3512-3514. doi: 10.1158/1078-0432.CCR-21-0749. Epub 2021 Apr 23.
Abstract
Current techniques for imaging prostate cancer (CT, MRI, and PET agents F-fluorodeoxyglucose, C-choline, C-acetate, and F-fluciclovine) are limited in sensitivity and specificity. PSMA PET agent Ga-PSMA-11 has recently been approved by the FDA. We comment on the performance of novel PSMA agent 18F-DCFPyL-PET/CT..
摘要
当前用于诊断前列腺癌的影像学技术（CT、MRI 和 PET 探针 F-氟代脱氧葡萄糖、C-胆碱、C-乙酸和 F-氟代赖氨酸）的敏感性和特异性均有限。PSMA PET 探针 Ga-PSMA-11 最近已获得 FDA 批准。我们对新型 PSMA 探针 18F-DCFPyL-PET/CT 的性能进行了评价。
相似文献
1
How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer?PSMA 抑制剂 18F-DCFPyL-PET-CT 图像对前列腺癌的诊断准确率如何？
Clin Cancer Res. 2021 Jul 1;27(13):3512-3514. doi: 10.1158/1078-0432.CCR-21-0749. Epub 2021 Apr 23.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
Metastasis-directed Therapy (SBRT) Guided by PET-CT F-CHOLINE Versus PET-CT Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness.基于 PET-CT F-CHOLINE 与 PET-CT Ga-PSMA 的转移灶导向治疗（SBRT）在去势敏感性寡转移前列腺癌中的疗效比较分析。
Clin Genitourin Cancer. 2021 Jun;19(3):230-236. doi: 10.1016/j.clgc.2020.08.002. Epub 2020 Aug 6.
4
Ga-PSMA-11 PET/CT in patients with occult biochemical recurrence of prostate carcinoma and negative F-Choline PET/CT. Preliminary assessment of its clinical use.镓-PSMA-11 PET/CT 在前列腺癌隐匿性生化复发且 F-胆碱 PET/CT 阴性的患者中的应用。初步临床评估。
Actas Urol Esp (Engl Ed). 2021 Jun;45(5):353-358. doi: 10.1016/j.acuroe.2021.04.008. Epub 2021 May 14.
5
Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal F-fluorocholine PET/CT: 1084 examinations.法国药品管理局（ANSM）对 Ga-PSMA-11 PET/CT 在 F-氟脱氧胆碱 PET/CT 阴性或不确定的前列腺癌生化复发中的成像方案、检出率和安全性的调查：1084 次检查。
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2935-2950. doi: 10.1007/s00259-020-05086-1. Epub 2021 Jan 8.
6
Comparative study of the most commonly-used radiopharmaceuticals for PSMA prostate PET/CT imaging.用于 PSMA 前列腺 PET/CT 成像的最常用放射性药物的比较研究。
Hell J Nucl Med. 2022 Jan-Apr;25(1):83-87. doi: 10.1967/s002449912437. Epub 2022 Apr 8.
7
Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.复发前列腺癌患者中[(18)F]DCFPyL与[(68)Ga]Ga-PSMA-HBED-CC用于PSMA-PET成像的比较
Mol Imaging Biol. 2015 Aug;17(4):575-84. doi: 10.1007/s11307-015-0866-0.
8
Comparison of Ga-PSMA-11 and F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence.10 例前列腺癌复发患者的 Ga-PSMA-11 和 F-Fluciclovine PET/CT 比较病例系列研究
J Nucl Med. 2018 May;59(5):789-794. doi: 10.2967/jnumed.117.203257. Epub 2017 Dec 14.
9
Diagnostic value of F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative Ga-PSMA PET/CT.18F-FDG PET/CT 对生化复发前列腺癌且 Ga-PSMA PET/CT 阴性患者的诊断价值。
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2970-2977. doi: 10.1007/s00259-021-05221-6. Epub 2021 Feb 2.
10
An F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with F-JK-PSMA-7 During the First Year of Application.一种 F 型 PSMA 配体用于前列腺癌的 PET/CT：F-JK-PSMA-7 在应用的第一年中的首例人体观察性研究和临床经验。
J Nucl Med. 2020 Feb;61(2):202-209. doi: 10.2967/jnumed.119.229542. Epub 2019 Jul 19.
引用本文的文献
1
MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer.用于评估前列腺癌进展和治疗抗性的胞外区域B纤连蛋白的磁共振分子成像
Chem Biomed Imaging. 2024 Jun 11;2(8):560-568. doi: 10.1021/cbmi.4c00002. eCollection 2024 Aug 26.
2
PSMA-based F-DCFPyL PET: a better choice than multiparametric MRI for prostate cancer diagnosis?基于前列腺特异性膜抗原（PSMA）的F-DCFPyL正电子发射断层扫描（PET）：在前列腺癌诊断中比多参数磁共振成像（MRI）是更好的选择吗？
Am J Nucl Med Mol Imaging. 2022 Dec 15;12(6):195-200. eCollection 2022.
3
The performance of F-PSMA PET/CT in the detection of prostate cancer: a systematic review and meta-analysis.F-PSMA PET/CT 在前列腺癌检测中的性能：系统评价和荟萃分析。
Asian J Androl. 2022 Jul-Aug;24(4):373-379. doi: 10.4103/aja202162.
4
Short-duration dynamic [F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [F]DCFPyL PET/MR at 120 minutes.短时长动态[F]DCFPyL正电子发射断层显像（PET）与CT灌注成像用于定位前列腺癌中主要的前列腺内病变：与数字组织病理学对照验证及与120分钟时的[F]DCFPyL PET/MR比较
EJNMMI Res. 2021 Oct 15;11(1):107. doi: 10.1186/s13550-021-00844-0.
本文引用的文献
1
Diagnostic Performance of F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.F-DCFPyL-PET/CT 在生化复发前列腺癌男性患者中的诊断性能：来自 CONDOR Ⅲ期、多中心研究的结果。
Clin Cancer Res. 2021 Jul 1;27(13):3674-3682. doi: 10.1158/1078-0432.CCR-20-4573. Epub 2021 Feb 23.
2
PSMA-targeted Radiotracers versus F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.PSMA 靶向放射性示踪剂与 F 氟脱氧葡萄糖（18F-Fluciclovine）在明确治疗后前列腺癌生化复发检测中的比较：系统评价和荟萃分析。
Radiology. 2020 Jul;296(1):44-55. doi: 10.1148/radiol.2020191689. Epub 2020 May 12.
3
Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer.代谢成像在原发性、转移性和复发性前列腺癌诊断中的作用。
Curr Opin Oncol. 2020 May;32(3):223-231. doi: 10.1097/CCO.0000000000000625.
4
Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease.前列腺癌特异性 PET 放射性示踪剂：在复发性疾病中的临床应用综述。
Pract Radiat Oncol. 2018 Jan-Feb;8(1):28-39. doi: 10.1016/j.prro.2017.07.011. Epub 2017 Jul 20.
5
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.前列腺特异性膜抗原在正常、良性及恶性前列腺组织中的表达
Urol Oncol. 1995 Jan-Feb;1(1):18-28. doi: 10.1016/1078-1439(95)00002-y.
Zotero 插件